<bill session="116" type="h" number="3812" updated="2022-11-01T13:50:34Z">
  <state datetime="2019-07-17">REFERRED</state>
  <status>
    <introduced datetime="2019-07-17"/>
  </status>
  <introduced datetime="2019-07-17"/>
  <titles>
    <title type="display">REMEDY Act</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications.</title>
    <title type="short" as="introduced">Reforming Ever&#194;&#173;green&#194;&#173;ing and Manipulation that Extends Drug Years Act</title>
    <title type="short" as="introduced">REMEDY Act</title>
  </titles>
  <sponsor bioguide_id="M001180"/>
  <cosponsors>
    <cosponsor bioguide_id="W000800" joined="2019-07-17"/>
  </cosponsors>
  <actions>
    <action datetime="2019-07-17">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-07-17" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2019-07-18">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="s" number="1209" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Intellectual property"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-13T16:47:48Z" status="Introduced in House">Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY Act 

This bill addresses drug patents with respect to Food and Drug Administration (FDA) approval of a drug application.

Currently, when the owner of a brand-name drug approval sues a generic drug company for patent infringement based on the generic company's application for FDA approval of a generic version of the brand-name drug, there is generally a 30-month stay on the approval of the generic version. Under this bill, the stay goes into effect only if the lawsuit alleges infringement of a patent that claims the drug compound.

When the U.S. Patent and Trademark Office invalidates a patent for a drug, the FDA must update its list of relevant patents for the drug.</summary>
</bill>
